Disco Pharmaceuticals closed a €36 million seed round to advance targets discovered with its surfaceome platform, the company said. The funding will support formal preclinical development of surfaceome‑based candidates and expansion of discovery pipelines. In parallel, contract research organization Inotiv announced a partnership with Lithuanian multiomics analysis firm Vugene to integrate AI‑enabled multiomics into early drug discovery workflows. The Inotiv–Vugene collaboration pairs CRO resources with computational bioinformatics to improve efficacy and safety predictions in lead selection, reflecting increased investor and partner appetite for AI‑driven target and candidate discovery.